Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Thoracic Neoplasms » Respiratory Tract Neoplasms » Lung Neoplasms
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Neoplasms
Diseases [C] » Respiratory Tract Diseases [C08] » Respiratory Tract Neoplasms » Lung Neoplasms
Hierarchy View
Subtype Terms (8)
Adenocarcinoma of Lung
73 drugs (38 approved, 35 experimental)
Bronchial Neoplasms
16 drugs (9 approved, 7 experimental)
Carcinoma, Bronchogenic
20 drugs (13 approved, 7 experimental)
Mesothelioma, Malignant
103 drugs (55 approved, 48 experimental)
Multiple Pulmonary Nodules
5 drugs (4 approved, 1 experimental)
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (51)
Phase 3 Indicated Drugs (105)
Phase 2 Indicated Drugs (263)
interferon alpha-2b (Intron-A)
interferon gamma-1b (actimmune)
k562 cell line transfected with hcd40l and hgm-csf
lutetium dotatate lu-177 (Lutathera)
monoclonal antibody gd2 anti-idiotype vaccine
multi-valent pneumococcal conjugate vaccine
n-(4-hydroxyphenyl)all-trans retinamide
nitroglycerin (transderm-nitro)
Phase 1 Indicated Drugs (172)
allogeneic natural killer cells
anti-ny eso-1 tcr-transduced t cells
autologous dendritic cell adenovirus ccl21 vaccine
dec-205/ny-eso-1 fusion protein cdx-1401
egfrbi-armed autologous activated t cells
gpc3 and/or tgfβ targeting car-t cells
hgm-csf herpes simplex virus injection
klh conjugates of gd2l, gd3l, globo h, fucosyl gm1
mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes
mvf-her-2(628-647)-crl 1005 vaccine
Other Experimental Indicated Drugs (33)
Organization Involved with Phase 4 Indications (78)
Beijing Zheng Ju Medical Technology Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.
Brazilian Society of Thoracic Surgery
China Academy of Chinese Medical Sciences
Chinese Academy of Medical Sciences
Guangdong Association of Clinical Trials
Guangzhou Pharmaceucal Company Limited
Huazhong University of Science and Technology
Nanjing NingQi Medicine Science and Technology Co., Ltd.
National Cancer Institute (NCI)
National Institute for Tuberculosis and Lung Diseases, Poland
North Sichuan Medical University
Organization Involved with Phase 3 Indications (361)
Air Force Military Medical University, China
Australasian Lung Cancer Trials Group
Badalona Hospital Germans Trias i Pujol
Beijing Mabworks Biotech Co., Ltd.
BeyondSpring Pharmaceuticals Inc.
Blokhin's Russian Cancer Research Center
Blueprint Medicines Corporation
Bureau of Science and Technology of Guangxi Province, China
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
Central and Eastern European Oncology Group
Centre Hospitalier Intercommunal Creteil
Chinese Thoracic Oncology Group
Chinese University of Hong Kong
Danish Oncological Lung Cancer Group
Dutch Society of Physicians for Pulmonology and Tuberculosis
Eastern Cooperative Oncology Group
EBMT Solid Tumors Working Party
ECOG-ACRIN Cancer Research Group
EORTC Lung Cancer Cooperative Group
European Lung Cancer Working Party
European Organisation for Research and Treatment of Cancer
European Thoracic Oncology Platform
Federation of Italian Cooperative Oncology Groups
Giovanni Paolo II Oncology Institute, Bari
Gottfried Wilhelm Leibniz Universität Hannover
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Groupe Francais De Pneumo-Cancerologie
Groupe Français de Pneumo-Cancérologie
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico del Nord-Ovest
Gruppo Oncologico Italia Meridionale
Gruppo Oncologico Italiano di Ricerca Clinica
Guangdong Academy of Medical Sciences
Guangdong Province Clinical Trial Association
Hannover Clinical Trial Center GmbH
Hellenic Oncology Research Group
Hoosier Cancer Research Network
Innovent Biologics (Suzhou) Co. Ltd.
Intergroupe Francophone de Cancerologie Thoracique
Istituto Nazionale per lo Studio e la Cura dei Tumori
Japan Agency for Medical Research and Development
Japan Multinational Trial Organization
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Jilin Provincial Tumor Hospital
Laboratorio Elea S.A.C.I.F. y A.
Lotte & John Hecht Memorial Foundation
Martha-Maria Krankenhaus Halle-Dölau gGmbH
Medical University of South Carolina
Medicine Invention Design, Inc
Nanjing Sanhome Pharmaceutical, Co., Ltd.
National Cancer Institute, France
National Center for Complementary and Integrative Health (NCCIH)
National Health and Medical Research Council, Australia
National Hospital Organization Osaka National Hospital
Niigata University Medical & Dental Hospital
North Central Cancer Treatment Group
Northwest Oncology Cooperative Group
Radiation Therapy Oncology Group
Royal Marsden Hospital NHS Trust
Russian Foundation of Technological Development
Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung
Shanghai Chest Hospital, Shanghai, China
Shanghai Gebaide Biotechnology Co., Ltd.
Shanghai Junshi Bioscience Co.,Ltd.
Shanghai Municipal Science and Technology Commission
Shanghai University of Traditional Chinese Medicine
Shijiazhuang Pharma Group (CSPC)
State University of New York, Buffalo
State University of New York, Syracuse
Swami Rama Cancer Hospital and Research Institute
Swedish Lung Cancer Study Group
Swiss Group for Clinical Cancer Research
The Canadian College of Naturopathic Medicine
The Norwegian Lung Cancer Study Group
The Serbsky State Scientific Center for Social and Forensic Psychiatry
The University of Texas, Dallas
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
University of Alabama, Birmingham
University of British Columbia
University of California, Davis
University of California, San Diego
University of Campania Luigi Vanvitelli
University of Colorado, Denver
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Texas, San Antonio
University of Western Australia
University of Western Brittany
Vita-Salute University of Milano. Italy
Washington University in St. Louis
West Japan Thoracic Oncology Group
ZAO NeuroVita Clinic of Interventional and Restorative Neurology and Therapy
Organization Involved with Phase 2 Indications (603)
Acharya Tulsi Regional Cancer Treatment & Research Institute
Advanced Accelerator Applications
Albert Einstein Israelite Hospital
A.O. Ospedale di Circolo di Busto Arsizio
A.O. Ospedale di Circolo di Melegnano
A.O. Santa Maria Degli Angeli - Pordenone
A.O. Valtellina e Valchiavenna
Association of Urogenital Oncology (AUO)
AUSL Piacenza - Ospedale Guglielmo da Saliceto
AUSL Viterbo - Ospedale di Belcolle
Autonomous University of Madrid
Azienda Ospedaliera Ospedale Civile di Legnano
Azienda Ospedaliera San Camillo Forlanini
Azienda Ospedaliera San Gerardo di Monza
Azienda Ospedaliera San Giovanni Battista
Azienda Ospedaliera Santa Maria Degli Angeli
Azienda Ospedaliera Sant'Andrea, Roma
Azienda Ospedaliera S. Maria della Misericordia
Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno
Azienda Ospedaliera Universitaria Senese
Azienda Provinciale per i Servizi Sanitari della Provincia Autonoma di Trento
Azienda Sanitaria dell'Alto Adige
Azienda Sanitaria Locale n.2 Savonese
Bankhead-Coley Florida Biomedical Research Program
Bank of Cyprus Oncology Centre
Bankura Sammilani Medical College
Beijing Pearl Biotechnology Limited Liability Company
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Benxi City hospital of Chinese medicine
Big Ten Cancer Research Consortium
Biotech Pharmaceutical Co., Ltd.
B.P. Poddar Hospital and Medical Research Ltd.
British Columbia Cancer Agency
Camargo Pharmaceutical Services
Canadian Institutes of Health Research (CIHR)
Cancer Biotherapy Research Group
Cancer Research and Biostatistics Clinical Trials Consortium
Cancer Research Network of Nebraska
Cancer Therapeutics Research Group
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Casa di Cura Dott. Pederzoli - Peschiera del Garda
Central European Cooperative Oncology Group
Centre Georges Francois Leclerc
Chao Family Comprehensive Cancer Center
China Three Gorges University, Yichang, China
Chinese Lung Cancer Surgical Group
Chittaranjan National Cancer Institute
Choithram Hospital and Research Centre
Chongqing Precision Biotech Co., Ltd
City of Hope National Medical Center
Clifford Hospital, Guangzhou, China
Clinical Research Technology S.r.l.
Cooper Institute for Reproductive Hormonal Disorders
Cyclacel Pharmaceuticals, Inc.
Developmental Therapeutics Consortium
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
First Hospital of Shijiazhuang City
First People's Hospital of Foshan
First People's Hospital of Yulin
Fondazione Ricerca Traslazionale
Frontier Science Foundation, Hellas
GKNM Hospital, Coimbatore, India
Groupe Hospitalier Paris Saint Joseph
Grupo de Investigación y Divulgación Oncológica
Grupo Espanol de Tumores Neuroendocrinos (GETNE)
Grupo Gallego de Cancer de Pulmon
Guangdong Pharmaceutical University
Guangdong Province Association Study of Thoracic Oncology
Guangzhou Panyu Central Hospital
Gujarat Cancer & Research Institute
Haemato-Onkologische Praxis und Tagesklinik
Haining Health-Coming Biotech Co., Ltd.
Hellenic Cooperative Oncology Group
Herbert Irving Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
HonorHealth Research Institute
Hospital General Universitario de Castellón
Hospital Universitario Arnau de Vilanova de Lleida
Hospital Universitario Virgen Macarena
Hubei Clinical Research Collaboration Group
Hunan Provincal Tumor Hospital
Icahn School of Medicine at Mount Sinai
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
Indira Ghandhi Institute of Medical Science
Infinity Pharmaceuticals, Inc.
Institut de Cancerologie de l'Ouest Paul Papin
Institute of Oncology Dr. Rosell (IOR)
Instituto Nacional de Enfermedades Respiratorias
Integrated Community Oncology Network
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Tumori Giovanni Paolo II, BARI
James and Esther King Biomedical Research Program
James Graham Brown Cancer Center
Kanagawa Prefectural Cancer Center
Kansas Masonic Cancer Research Institute
Katholieke Universiteit Leuven
Kentucky Lung Cancer Research Program
Kliniken Nordoberpfalz AG Klinikum Weiden Medizinische Kliniken I
Kobe Minimally Invasive Cancer Center
Latin American Cooperative Oncology Group
Laura & Isaac Perlmutter Cancer Center
Liaohe Oil Field General Hospital
Lovelace Respiratory Research Institute
Ludwig Institute for Cancer Research
Malabar Institute of Medical Sciences
Maria Sklodowska Curie Children's Hospital
Medigen Biotechnology Corporation
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
Mt. Sinai Medical Center, Miami
National Cheng Kung University
National Comprehensive Cancer Network
National Hospital Organisation Nagoya Medical Centre
National Institutes of Health (NIH)
National University of Singapore
Netaji Subhash Chandra Bose Cancer Research Institute
New Mexico Cancer Care Alliance
Norwegian University of Science and Technology
Oregon Health and Science University
Ospedale Santa Croce-Carle Cuneo
Ospedale San Vincenzo Taormina
Ospedale S.M. della Misericordia
Owensboro Medical Health System
Personal Genome Diagnostics (PGDx)
Philipps University of Marburg
Phoenix Clinical Research Center
Postgraduate Institute of Medical Education and Research
Prologue Research International
Roy Castle Lung Cancer Foundation
R.S.T. Cancer Hospital & Research Centre
Samyang Biopharmaceuticals Corporation
Sarcoma Oncology Research Center, LLC
Shaanxi Provincial People's Hospital
Shanghai Cell Therapy Research Institute
Shanghai Houchao Biotechnology Co., Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Hank Bioengineering Institute
Shenzhen Hornetcorn Bio-technology Company, LTD
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Silvano Chiapparoli Logistica SpA
Southeastern Medical Oncology Center, Goldsboro
Southern Europe New Drug Organization (SENDO)
Southern Italy Cooperative Oncology Group
St. John Providence Health System
St. Joseph Hospital Health Center
St. Luke's-Roosevelt Hospital Center
Taiwan Chest Disease Association
Technical University of Munich
The First People's Hospital of Hangzhou
The First People's Hospital of Jingzhou
The First People's Hospital of Lianyungang
The People's Hospital of Liaoning Province
The Second People's Hospital of Sichuan
Translational Oncology Research International
Translational Research Informatics Center, Kobe, Hyogo, Japan
Translational Research in Oncology
Trans Tasman Radiation Oncology Group
Universidad Complutense de Madrid
University Hospital of North Norway
University Hospital Quirón Dexeus, Barcelona
University of California, Berkeley
University of California, Irvine
University of California, Los Angeles
University of California, San Francisco
University of Illinois at Chicago
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Southern California
University of Technology, Sydney
University of Texas, Galveston
Vestre Viken Ringerike Sykehus
Western Economic Diversification Canada
Organization Involved with Phase 1 Indications (117)
Asbestos Diseases Research Foundation
Askelios Klinik München Gauting
Cancer Immunotherapy Trials Network
Center Trials & Treatment Inc.
Central European Society for Anticancer Drug Research (CESAR)
Comprehensive Cancer Centers of Nevada
Guangzhou Bio-gene Technology Co., Ltd.
Guangzhou Yiyang Biological Technology Co., Ltd.
Hunan Yongren Medical Innovation Co. Ltd.
Hunan Zhaotai Yongren Biotech Co. Ltd.
Jiangxi Provincial Cancer Hospital
National Heart, Lung, and Blood Institute (NHLBI)
National Hospital Organisation Kyushu Cancer Centre
National Institute for Health Research, United Kingdom
Northwest Cancer Specialists, P.C.
Polyphenon E International,Inc.
Organization Involved with Other Experimental Indications (18)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
